Pharmaceutical

Shionogi awarded $375m from HHS for preventative Covid-19 injectable

Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao via Getty Images.

Jan 18, 2025 - 06:00
Shionogi awarded $375m from HHS for preventative Covid-19 injectable
Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao via Getty Images.
Read the original article

Tags:

Previous Article

JPM 2025: Lonza shares outlook on CHI exit and acquisition strategy

Next Article

IMPACT ovarian cancer capsules authorised in China

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Dana-Farber blindsided Brigham and Women’s. The blowback will be strong

STAT+: Dana-Farber blindsided Brigham and Women’s. The ...

Sep 16, 2023

ImPact enters partnership for pathologic myopia therapy development

ImPact enters partnership for pathologic myopia therapy...

Aug 14, 2023

STAT+: FDA advisers vote against approving Intercept’s NASH drug

STAT+: FDA advisers vote against approving Intercept’s ...

May 19, 2023